Vir Bio Phase 2 flu prevention trial misses endpoints; cash ~$1.9B

Vir Biotechnology, Inc.

Phase 2 PENINSULA trial of VIR-2482 did not meet primary or secondary efficacy endpoints for preventing symptomatic influenza A.
Highest dose (1,200 mg) showed non-statistically significant 16% reduction in protocol-defined influenza A illness vs placebo.
Secondary endpoint (CDC-defined ILI) showed 57% reduction, but not statistically significant (95% CI -2.51 to 82.15).
VIR-2482 was generally well tolerated; no safety signals identified; ~3,000 participants enrolled.
Cash, cash equivalents and investments were approximately $1.9 billion as of June 30, 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vir Biotechnology, Inc. reported preliminary financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: preliminary results

Exact text from the filing

Although it has not finalized its full financial results for the quarter ended June 30, 2023, Vir Biotechnology, Inc. (the “Company”) disclosed in a press release on July 20, 2023, that it had cash, cash equivalents and investments of approximately $1.9 billion as of June 30, 2023.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-190147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.